Scarica l'app Stockscreener
1.735
11.22%
0.175
Dopo l'orario di chiusura:
1.76
0.025
+1.44%
Femasys Inc Borsa (FEMY) Ultime notizie
Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control - GlobeNewswire Inc.
Form 4 Femasys Inc For: 29 September By Investing.com - Investing.com Nigeria
Femasys Inc (NASDAQ: FEMY) Share Price, FEMY Stock News, FEMY Share Price & Updates - Kalkine
Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio - Yahoo Finance
Femasys Company Profile & Introduction - Moomoo
Stonepine Capital Management, LLC Buys Femasys Inc (FEMY) -- Shares Look 70% Undervalued on GF Value - GuruFocus
FemasysFiles For Resale Of Up To 28,124,997 Shares Of Common StockSEC Filing - TradingView
Substantial share sale risk at Femasys (NASDAQ: FEMY) - Stock Titan
Femasys Inc (FEMY) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Stonepine group flags new Femasys (NASDAQ: FEMY) position investors will want to size - Stock Titan
Femasys (FEMY) Stock News & Analysis - TechStock²
Femasys partners with UNC Health for fertility services By Investing.com - Investing.com India
Femasys partners with UNC Health for fertility services By Investing.com - Investing.com Canada
Femasys partners with UNC Health for fertility services By Investing.com - Investing.com UK
Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations - The Manila Times
Femasys (FEMY) Stock: Finishes 8.42% Higher at $2.96 on the Day; Current Setup: the Supplied Trading Band Runs From $2.81 to $3.11 on the DayValue Stock Ideas - vinanet.vn
Femasys (FEMY) Stock: Finishes 8.42% Higher at $2.96 on the Day; Current Setup: the Supplied Trading Band Runs From $2.81 to $3.11 on the DayComposite Profile - dars.gov.et
Femasys (FEMY) Snapshot: Rises 4.58% to $2.85 in the Current Update; Immediate View: $2.71 and $2.99 Define the Nearby Reference Levels in the Latest ReadingVolume Dry Up - vinanet.vn
Femasys (FEMY) Snapshot: Rises 4.58% to $2.85 in the Current Update; Immediate View: $2.71 and $2.99 Define the Nearby Reference Levels in the Latest ReadingHagopian Line - siam.in
Femasys (FEMY): Moves 0.74% Higher to $2.73 for the Current Session; the Session Ends Within the Reported Technical Boundaries in Latest TradingVolatility Smirk - vinanet.vn
Biotech Femasys (NASDAQ: FEMY) raises $30M in private round - Stock Titan
Femasys Secures FDA Pathway for Non-Surgical Contraceptive - Sahm
Femasys Jumps as FDA Clears Modular Review Path for Non-Surgical Birth Control - finance.biggo.com
Why Is Femasys Stock Soaring Today?Femasys (NASDAQ:FEMY) - Benzinga
FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential - Stocktwits
FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential - TradingView
Femasys receives FDA approval for modular PMA pathway for FemBloc By Investing.com - Investing.com Nigeria
Femasys (FEMY) Results Versus Estimates: EPS Beats Its Estimate in the Latest Reading; Latest Reaction: Shares Move 24.32% Up for the Current SessionLow Growth Earnings - Vinanet
Femasys Secures FDA Approval for Modular PMA Pathway for FemBloc - Yahoo Finance
Femasys receives FDA approval for modular PMA pathway for FemBloc - Investing.com
FDA approves a modular review path for Femasys’ permanent birth control - Stock Titan
Femasys receives FDA approval for modular PMA pathway for FemBloc By Investing.com - Investing.com India
Femasys Inc. Announces FDA Approval of Modular PMA Pathway for FemBloc in the U.S. - Quiver Quantitative
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc® - Caledonian Record
Femasys Announces FDA Approval Of Modular Pma Submission Approach For Fembloc - TradingView
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc® - marketscreener.com
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc® - Yahoo Finance
Femasys (FEMY) Results Versus Estimates: EPS Beats Its Estimate in the Latest Reading; Latest Reaction: Shares Move 24.32% Up for the Current SessionAnalyst Coverage Count - dars.gov.et
Femasys secures $30 million to advance fertility portfolio - The Pharma Letter
Lake Street Maintains Femasys(FEMY.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Nantahala's $12M deal brings board influence at Femasys (NASDAQ: FEMY) - Stock Titan
FEMY Q1 2026 Earnings: Loss Beat Estimates, Stock Slips 1.31%Earnings Turnaround - vinanet.vn
Maxim Group Maintains Femasys(FEMY.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Femasys Stock Price Forecast. Should You Buy FEMY? - StockInvest.us
Femasys Q2 EPS $(1.08) beats estimate; sales rise 85% - scanx.trade
Femasys (NASDAQ: FEMY) cuts net loss and secures $30M private funding - Stock Titan
Femasys reports $331,827 Q2 revenue, $4.47M net loss and $30M financing to support U.S. commercial push - TradingView
Femasys Reports $331,827 Q2 Revenue and $4.47 Million Net Loss - Quiver Quantitative
Femasys Inc. (NASDAQ: FEMY) narrows first-half loss, completes $30M financing - Stock Titan
Femasys 2Q Loss/Shr $1.33 >FEMY - Moomoo
2.01%
0.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):